Yu.O. Nikolaeva

Yu.O. Nikolaeva

Auto-generated profile, based on publicly available information

Yu.O. Nikolaeva

Russian University of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
AOA.YU. Ovchinnikov
A.YU. Ovchinnikov
NMN.A. Miroshnichenko
N.A. Miroshnichenko
YNYu.O. Nikolaeva
Yu.O. Nikolaeva
Sore throat is the leading symptom of acute tonsillopharyngitis associated with previous acute respiratory viral infections, including COVID-19. The pathogenesis of these nosologies is based on the cumulative result of the primary direct damaging effect of viruses and secondary alternative inflammatory changes in the mucosal epithelium in the focus of infection, which, against the background of changes in the functions of the regional microbiota, leads to the development of viral-bacterial inflammation that goes beyond the protective-reparative level. In the treatment of acute tonsillopharyngitis after exclusion of GABHS etiology, topical etiotropic drugs are often used. It is desirable to achieve a uniform distribution of active ingredients, and to maximize the use of additional pharmacological capabilities (irrigation-eliminative action, reparative effect). To build up the evidence base for the effectiveness of just such medicines on the basis of the Department of Otorhinolaryngology of the Moscow State Medical University named after. A.I. Evdokimov, an observational prospective comparative study was conducted, using, in addition to the clinical assessment method, cytomorphological approaches (cytomorphometry). The results of the study demonstrated that gargling with a solution of hydroxymethylquinoxylindioxide (Dioxydin 0.25 mg/ml solution for topical application) in adult patients with acute tonsillopharyngitis provides rapid relief of pain, a decrease in the severity of inflammation symptoms, and also makes it possible to achieve limitation of the degree of destruction of the epithelium in the height of inflammation and a more complete and rapid recovery of the damaged mucous membrane by the time of recovery.

14 November 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AOA. Yu. Ovchinnikov
A. Yu. Ovchinnikov
NMN. A. Miroshnichenko
N. A. Miroshnichenko
YNYu. O. Nikolaeva
Yu. O. Nikolaeva
MVM. M. Vasilyev
M. M. Vasilyev
Increase in the number of acute and chronic diseases is a global trend. On the one hand, the emergence of new types of viruses, their active mutation, an increase in antibiotic-resistant bacterial strains, a high frequency of immunodeficiency and allergic diseases contribute to this. On the other hand is inadequate treatment of inflammatory diseases of the upper respiratory tract, widespread use of systemic antibiotics without indications. The use of bioregulatory medicines with proven efficacy in the complex treatment can reduce the drug load on the body, reduce the bacterial complications and side effects. Traumeel®S joins the physiological course of inflammation and activates pro-resolving mediators, contributes to its faster completion and tissue repair. The efficacy and safety of Traumeel®S has been confirmed in many randomized clinical trials. The drug has proven its value in almost any inflammatory pathology of the upper respiratory tract and ear. The drug Lymphomyosot®, a multicomponent agent with lymphatic drainage action, has proven itself perfectly in the complex therapy of chronic tonsillitis. In November 2019, the Council of Experts of the National Medical Association of Otorhinolaryngologists on the problems of pathology of the lympharyngeal ring was held. It is recommended to use the multicomponent bioregulatory preparation Traumeel®S to correct the inflammatory process, which has shown in studies a modulating effect on inflammatory mediators without suppressing COX-2 (prostaglandins). With exacerbation of chronic tonsillitis and lymphadenitis of nonspecific etiology, it is possible to use the multicomponent preparation Lymphomyosot®, which helps to improve the drainage and detoxification function of the lymphatic system.

13 October 2024 in Consilium Medicum
Verified
Journal Article
Open access
PDF file
AZAndrey A. Zaytsev
Andrey A. Zaytsev
NMNina A. Miroshnichenko
Nina A. Miroshnichenko
AOAndrey Yu. Ovchinnikov
Andrey Yu. Ovchinnikov
YNYulia O. Nikolaeva
Yulia O. Nikolaeva
ЗАЗайцев Андрей Алексеевич
Зайцев Андрей Алексеевич
There are diseases for which people turn to specific specialists, but there are also a number of ones that are treated by doctors of different specialties. Therapists, infectious disease specialists, otolaryngologists, and pulmonologists diagnose and treat acute respiratory viral infections. But the same specialists often have to deal with the outcomes of an acute process – postnasal drip and post-infectious cough, which decreases the quality of life and exhaust patients. However, in case when the correct diagnosis is made, there are treatment regimens that allow to achieve quick relieve subjective and objective symptoms, as well as clinical cure of the disease escaping the use of antibacterial therapy. The efficient therapy agreement of the otolaryngologist and pulmonologist is that for various causes of cough, herbal medicine is the best choice.

12 May 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AOA. Yu. Ovchinnikov
A. Yu. Ovchinnikov
NMN. A. Miroshnichenko
N. A. Miroshnichenko
KSK. V. Savranskaya
K. V. Savranskaya
YNYu. O. Nikolaeva
Yu. O. Nikolaeva
The article is devoted to the treatment of one of the most common diseases - the treatment of rhinosinusitis. According to statistics only 2% of the sinusitis in population are bacterial. At the same time administration of systemic antibiotic therapy reaches 95.5%. The problem of rational prescription of antibacterial drugs, including management of the rhinosinusitis, is very acute, especially considering the constant increase in the number of antibiotic-resistant microorganisms. Currently, the level of patients with prolonged post-viral rhinosinusitis after COVID-19 has increased. Most have a history of one or more courses of systemic antibiotics and, often, without indications. In article are listed indications for systemic and local antibacterial therapy in adults and children, based on national and European clinical guidelines. The data on complications during the use of systemic antibacterial drugs are presented. Authors give information about the advantages of the local use of antibiotics: the absence of general toxic complications, the creation of an optimal concentration directly in the focus of inflammation. The advantages of combining solutions of neomycin and polymyxin B for topical use, such as a pronounced bactericidal effect against gram-positive and gram-negative bacteria (Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa), causing the development of infectious processes in the upper respiratory tract, are separately noted. The author describes his own experience of using the original nasal spray Polydex with phenylephrine, containing a fixed combination of neomycin, polymyxin B, dexamethasone sodium metasulfobenzoate and phenylephrine, in the treatment of patients with post-viral rhinosinusitis. As a result of the collection of literature data, as well as based on their own experience, the authors concluded that the use of this nasal spray in outpatient practice will significantly improve the effectiveness of treatment and reduce the frequency of prescribing systemic antibiotics.

1 January 2022 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
AOA.YU. Ovchinnikov
A.YU. Ovchinnikov
NMN.A. Miroshnichenko
N.A. Miroshnichenko
YNYu.O. Nikolaeva
Yu.O. Nikolaeva
Пациенты с аллергическим ринитом (АР) имеют предрасположенность к частым острым респираторным вирусным инфекциям (ОРВИ). Воспаление слизистой оболочки полости носа и околоносовых пазух у таких больных более выраженное на фоне сочетания аллергического и инфекционного воспаления. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние терапии с применением современных антигистаминных препаратов на состояние и выраженность симптомов у взрослых пациентов с обострением АР, вызванного пыльцой растений (САР), и развитием ОРВИ. МАТЕРИАЛ И МЕТОДЫ На кафедре оториноларингологии ФГБОУ ВО «МГМСУ им. А.И. Евдокимова» Минздрава России с апреля по август 2021 г. проведено наблюдательное исследование. Включены пациенты обоих полов в возрасте от 18 до 65 лет с ранее (не менее 1 года назад) верифицированным диагнозом САР легкой и средней степени тяжести в стадии обострения, обратившиеся за медицинской помощью по поводу ОРВИ. Всем больным назначали терапию с включением препарата, относящегося к фармакологической группе антигистаминных препаратов 2-го поколения (АГП-2п) (курсом 14 дней). Кроме того, больные получали по показаниям симптоматическую терапию ОРВИ, включая назальные деконгестанты (по потребности), жаропонижающие и противокашлевые препараты. РЕЗУЛЬТАТЫ На основании полученных данных удалось доказать, что применение современных антигистаминных препаратов у пациентов, коморбидных в отношении АР и ОРВИ, оказывает выраженное лечебное действие. Теоритин обеспечивает терапевтический эффект в ранние сроки в отношении назальных и неназальных симптомов сезонного обострения АР/ОРВИ, а также быстро улучшает качество жизни пациентов, что делает перспективным его применение для лечения ОРВИ на фоне АР. Препарат имеет сопоставимую с цетиризином противогистаминную активность и превосходит его по способности подавлять аллергическую воспалительную реакцию, например на коже, а также по длительности сохранения антигистаминного эффекта. ЗАКЛЮЧЕНИЕ Представленные результаты свидетельствуют об эффективности теоритина и цетиризина в лечении пациентов с сезонным обострением аллергического ринита, коморбидных по острым респираторным вирусным инфекциям.

8 April 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
AOA. Yu. Ovchinnikov
A. Yu. Ovchinnikov
NMN. A. Miroshnichenko
N. A. Miroshnichenko
YNYu. O. Nikolaeva
Yu. O. Nikolaeva
Introduction. In conditions of widespread resistance of pathogens to traditional antimicrobial drugs, active attention is paid to the development of topical antimicrobial drugs for the effective treatment of inflammatory pathology of the middle ear.Aim. To study the efficacy and safety of a new dosage form of the drug Dioxydin® (2.5 mg/ml ear drops) in the treatment of patients with acute purulent otitis media and exacerbation of chronic purulent otitis media in comparison with ear drops containing 0.3% ciprofloxacin solution.Materials and methods. A multicenter randomized comparative clinical trial included adults with acute purulent otitis media or exacerbation of chronic purulent otitis media and during 6 face-to-face visits (days 1st, 3rd, 6th, 9th, as well as a therapy completion visit and a follow-up visit), the effect of drugs was evaluated according to examination, otoscopy, microbiological and audiometric examinations. Safety was assessed by the frequency of adverse events and the results of blood, urine tests and vital signs.Results. The achievement of the primary criteria was evaluated among 164 participants randomized into 2 groups: the proportion of patients with no indications for systemic antibacterial therapy at Visit 2 and with no ear pain at Visit 4, Dioxydin® ear drops had no less effectiveness than the comparison drug (64.6 and 89.9% versus 68.3 and 87.3%, respectively). In terms of the frequency of elimination of the pathogen and improvement of air conduction, the compared drugs also had no statistically significant differences, and according to some secondary criteria, Dioxydin® significantly exceeded 0.3% ciprofloxacin solution (the proportion of patients with a pronounced decrease in pain and congestion in the ear, as well as hyperemia of the eardrum). According to the safety criteria, the compared drugs had no significant differences.Conclusions. The results of the study confirmed the high efficacy and safety of Dioxydin® ear drops in the treatment of otitis media in adults.